Hematopoietic cell transplantation for congenital bone marrow failure

Current Opinion in Oncology

Volumn 17, Issue 2, 2005, Pages 106-113

  MacMillan, Margaret L ^a,b   Wagner, John E ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Congenital marrow failure; Diamond Blackfan anemia; Fanconi anemia; Hematopoietic cell transplantation

Indexed keywords

BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; OXYMETHOLONE; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW; BONE MARROW DISEASE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; T CELL DEPLETION; UMBILICAL CORD;

BONE MARROW DISEASES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, HOMOLOGOUS;

EID: 17144420864     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000152977.55175.5b     Document Type: Review

References (51)

1. Alter B, Young N. The bone marrow failure syndromes. In Hematology of Infancy and Childhood. 5th ed. Edited by Nathan DG. Philadelphia: WB Saunders; 1998:237-335.
2. Sieff CA, Nisbet-Brown E, Nathan DG. Congenital bone marrow failure syndromes. Br J Haematol 2000; 111:30-42.
3. Manji A, Fernandez C, Yanofsky R, et al. Characterization of hematological phenotype of the inherited marrow failure syndromes: report from the Canadian Inherited Marrow Failure Registry (CIMFR). Blood 2003; 102:500a.
4. Wagner JE, MacMillan ML, Auerbach AD. Hematopoietic cell transplantation for Fanconi anemia. In Hematopoietic Cell Transplantation. 3rd ed. Edited by Blume KG, Forman SJ, Appelbaum FR. Maiden: Blackwell Sciences Ltd.; 2004:1483-1504. This is a thorough review of FA, especially the role of HCT in its treatment.
5. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101:1249-1256.
6. Butturini A, Gale RP, Verlander PC, et al. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 1994; 84:1650-1655.
7. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood 2003; 101:822-826. These results of a survey show that FA patients had a 785-fold higher risk of leukemia and a 48-fold higher risk of solid tumors, especially of the head and neck, esophagus, and vulva.
8. Deeg HJ, Socie G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87:386-392.
9. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003; 129:106-112. This report of International Fanconi Anemia Registry results show that the cumulative incidence of hematologic neoplasms and solid tumors by age 40 in FA patients is 33% and 28%, respectively.
10. Gluckman E, Devergie A, Schaison G, et al. Bone marrow transplantation in Fanconi anaemia. Br J Haematol 1980; 45:557-564.
11. Gluckman E, Devergie A, Dutreix J. Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol 1983; 54:431-440.
12. Gluckman E, Auerbach AD, Horowitz MM, et al. Bone marrow transplantation for Fanconi anemia. Blood 1995; 86:2856-2862.
13. MacMillan ML, Auerbach AD, Davies SM, et al. Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial. Br J Haematol 2000; 109:121-129.
14. Guardiola P, Pasquini R, Dokal I, et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood 2000; 95:422-429.
15. Wagner JE, Auerbach AD, Gandham S, et al. Unrelated donor hematopoietic cell transplantation (UD-HCT) for Fanconi anemia (FA): impact of patients age, pretransplant performance status, prior androgens and fludarabine based conditioning on survival. Blood 2001; 98:814a. The National Marrow Donor Program data from 91 FA patients undergoing unrelated donor HCT were analyzed. Less GVHD was observed in recipients of TCD marrow. Better survival was associated with younger patients, good performance status, no history of androgen use, and the use of FLU in a preparative regimen.
16. IBMTR/ABMTR Newsletter 1 February 2002. In this analysis of IBMTR data of 94 FA patients who underwent transplantation with alternative donor HCT, malformations (≥3), use of androgens before HCT, positive recipient cytomegalovirus serology, and use of female donor were associated with poor survival.
17. Socie G, Devergie A, Girinski T, et al. Transplantation for Fanconi's anaemia: long-term follow-up of fifty patients transplanted from a sibling donor after low-dose cyclophosphamide and thoraco-abdominal irradiation for conditioning. Br J Haematol 1998; 103:249-255.
18. Guardiola P, Socie G, Li X, et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood 2004; 103:73-77. This important paper shows acute GVHD to be associated with a 33-fold increased risk for the development of squamous cell cancers in FA patients.
19. Rosenberg PS, Socie G, Alter BP, et al. Risk of head and neck squamous cell cancer and death in transplanted and untransplanted patients with Fanconi anemia. Blood 2004, Aug 26 (Epub ahead of print). This report shows that acute and chronic GVHD are significant risk factors for the development of squamous cell cancers in FA patients.
20. Roy V, Perez W, Marsh J, et al. Bone marrow transplantation for Diamond-Blackfan anemia: report of the International Bone Marrow Transplant Registry experience. Blood 2003; 102:245a. This report from the IBMTR registry gives the results of allogeneic HCT in 61 patients with DBA. Patients with good performance status and recipients of HLA-identical sibling donors had better outcomes.
21. Campagnoli MF, Garelli E, Quarello P, et al. Molecular basis of Diamond-Blackfan anemia: new findings from the Italian registry and a review of the literature. Haematologica 2004; 89:480-489. This is a report on the clinical and molecular data from 97 DBA patients from the Italian registry, including 12 who underwent HCT, and a review of the literature.
22. Shaw PH, Haut PR, Olszewski M, et al. Hematopoietic stem-cell transplantation using unrelated cord-blood versus matched sibling marrow in pediatric bone marrow failure syndrome: one center's experience. Pediatr Transplant 1999; 3:315-321.
23. Tamary H, Yaniv I, Stein J, et al. A clinical and molecular study of a Bedouin family with dysmegakaryopoiesis, mild anemia, and neutropenia cured by bone marrow transplantation. Eur J Haematol 2003; 71:196-203.
24. Milledge J, Shaw PJ, Mansour A, et al. Allogeneic bone marrow transplantation: cure for familial Mediterranean fever. Blood 2002; 100:774-777.
25. Remacha AF, Badell I, Pujol-Moix N, et al. Hydrops fetalis-associated congenital dyserythropoietic anemia treated with intrauterine transfusions and bone marrow transplantation. Blood 2002; 100:356-358.
26. Iolascon A, Sabato V, de Mattia D, et al. Bone marrow transplantation in a case of severe, type II congenital dyserythropoietic anaemia (CDA II). Bone Marrow Transplant 2001; 27:213-215.
27. Ghavamzadeh A, Alimoghadam K, Nasseri P, et al. Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. Bone Marrow Transplant 1999; 23:299-301.
28. Rocha V, Devergie A, Socie G, et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998; 103:243-248.
29. Bertrand Y, Muller SM, Casanova JL, et al. Reticular dysgenesis: HLA non-identical bone marrow transplants in a series of 10 patients. Bone Marrow Transplant 2002; 29:759-762.
30. Berthet F, Siegrist CA, Ozsahin H, et al. Bone marrow transplantation in cartilage-hair hypoplasia; correction of the immunodeficiency but not of the chondrodysplasia. Eur J Pediatr 1996; 155:286-290.
31. MacMillan ML, Davies SM, Wagner JE, et al. Engraftment of unrelated donor stem cells in children with familial amegakaryocytic thrombocytopenia. Bone Marrow Transplant 1998; 21:735-737.
32. Lackner A, Basu O, Bierings M, et al. Haematopoietic stem cell transplantation for amegakaryocytic thrombocytopenia. Br J Haematol 2000; 109:773-775.
33. Lonial S, Bilodeau PA, Langston AA, et al. Acquired amegakaryocytic thrombocytopenia treated with allogeneic BMT: a case report and review of the literature. Bone Marrow Transplant 1999; 24:1337-1341.
34. Grewal SS, Barker JN, Davies SM, et al. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003; 101:4233-4244.
35. Grewal SS, Kahn JP, MacMillan ML, et al. Successful hematopoietic stem cell transplantation for Fanconi anemia from an unaffected HLA-genotype- identical sibling selected using preimplantation genetic diagnosis. Blood 2004; 103:1147-1151. This report describes the first successful HCT in a case of in vitro fertilization and preimplantation genetic diagnosis.
36. Aker M, Varadi G, Slavin S, et al. Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi anemia. J Pediatr Hematol Oncol 1999; 21:237-239.
37. Kapelushnik J, Or R, Slavin S, et al. A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia. Bone Marrow Transplant 1997; 20:1109-1110.
38. Ebell W. Update of the German Fanconi Anemia (GEFA) transplant protocol: indications, results and risk factors. In: Fourteenth Annual International Fanconi Anemia Scientific Symposium. December 5, 2002, Philadelphia, Pennsylvania; p. 55.
39. MacMillan ML, Auerbach AD, Champagne MA, et al. High probability of survival after related and alternate donor hematopoietic cell transplantation for Fanconi anemia using fludarabine based preparative therapy. Blood 2003; 102:465a. This report shows excellent engraftment, low rates of GVHD, and good survival rates in FA patients at standard after HCT using a FLU-based preparative regimen and TCD bone marrow or UCB.
40. Zanis-Neto J, de Medeiros CR, Bitencourt MA, et al. Bone marrow transplantation (BMT) for Fanconi anemia (FA), decreasing the cyclophosphamide dose without irradiation. Blood 2003; 102:972a. This report describes successful engraftment and good survival in FA patients undergoing HCT without the use of irradiation.
41. de la Fuente J, Reiss S, McCloy M, et al. Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors. Bone Marrow Transplant 2003; 32:653-656. This case report describes successful HCT using a nonirradiation, FLU-based preparative regimen for two FA patients.
42. Maschan AA, Trakhtman PE, Balashov DN, et al. Fludarabine, low-dose busulfan and antithymocyte globulin as conditioning for Fanconi anemia patients receiving bone marrow transplantation from HLA-compatible related donors. Bone Marrow Transplant 2004; 34:305-307. This report describes successful HCT using a nonirradiation, FLU-based preparative regimen for FA patients.
43. Ebell W. Current results, pharmacokinetics and chimerism analyses in FA patients receiving unrelated transplants according to the GEFA protocol. In: Fifteenth Annual Fanconi Anemia Research Fund Scientific Symposium; October 18, 2003; Houston, Texas; p. 39. This is a report on a nonirradiation, busulfan-based preparative regimen for FA patients with good engraftment and low rates of GVHD.
44. Boyer MW, Gross TG, Loechelt B, et al. Low risk of graft-versus-host disease with transplantation of CD34 selected peripheral blood progenitor cells from alternative donors for Fanconi anemia. J Pediatr Hematol Oncol 2003; 25:890-895. This is a report on a FLU-based preparative regimen for alternative-donor HCT for FA.
45. Boulad F, Auerbach AD, Small TN, et al. Fludarabine (Flu) based preparative cytoreductive regimen and t-cell depleted grafts from unrelated or mismatched related donors. In: Fifteenth Annual Fanconi Anemia Research Fund Scientific Symposium; October 18, 2003; Houston, Texas; 2003; p. 37. This is a report on FLU-based preparative therapy followed by TCD peripheral blood progenitor cell HCT in FA patients showing low rates of GVHD.
46. Gomez-Almaguer D, Ruiz-Arguelles GJ, Tarin-Arzaga LC, et al. Reduced-intensity stem cell transplantation in children and adolescents: the Mexican experience. Biol Blood Marrow Transplant 2003; 9:157-161.
47. Florencio R, Ostronoff M, Matias C, et al. Report of a successful non myeloablative BMT in a transfusion dependent child with Diamond Blackfan Anemia. Blood 2003; 102:436b. This paper reports successful nonmyeloablative HLA-identical sibling donor HCT in a patient with DBA.
48. Ostronoff M, Florencio R, Campos G, et al. Successful nonmyeloablative bone marrow transplantation in a corticosteroid-resistant infant with Diamond-Blackfan anemia. Bone Marrow Transplant 2004; 34:371-372. This paper reports a successful nonmyeloablative HLA-identical sibling donor HCT in an infant with DBA.
49. Dror Y, Freedman MH, Leaker M, et al. Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant 2003; 31:847-850. This paper reports successful unrelated donor BMT after FLU-based preparative therapy for dyskeratosis congenita.
50. Gungor T, Corbacioglu S, Storb R, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for treatment of dyskeratosis congenita. Bone Marrow Transplant 2003; 31:407-410. This case report describes successful HLA-identical sibling peripheral blood progenitor cell HCT after nonmyeloablative preparative therapy for patient with dyskeratosis congenita.
51. Al-Ahmari A, Ayas M, Al-Jefri A, et al. Allogeneic stem cell transplantation for patients with congenital amegakaryocytic thrombocytopenia (CAT). Bone Marrow Transplant 2004; 33:829-831. This report describes busulfan-based preparative therapy for patients with amegakaryocytic thrombocytopenia undergoing HCT.